Cargando…
Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients
BACKGROUND: Tumour hypoxia promotes an aggressive tumour phenotype and enhances resistance to anticancer treatments. Following the recent observation that the mitochondrial inhibitor atovaquone increases tumour oxygenation in NSCLC, we sought to assess whether atovaquone affects tumour subregions di...
Autores principales: | Bourigault, Pauline, Skwarski, Michael, Macpherson, Ruth E., Higgins, Geoff S., McGowan, Daniel R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716680/ https://www.ncbi.nlm.nih.gov/pubmed/34964932 http://dx.doi.org/10.1186/s13550-021-00871-x |
Ejemplares similares
-
Timing of hypoxia PET/CT imaging after 18F-fluoromisonidazole injection in non-small cell lung cancer patients
por: Bourigault, Pauline, et al.
Publicado: (2022) -
The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia
por: Ashton, Thomas M., et al.
Publicado: (2016) -
Whole tumor kinetics analysis of (18)F-fluoromisonidazole dynamic PET scans of non-small cell lung cancer patients, and correlations with perfusion CT blood flow
por: McGowan, Daniel R., et al.
Publicado: (2018) -
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma
por: McGowan, Daniel R., et al.
Publicado: (2019) -
PET imaging of tumour hypoxia
por: Padhani, Anwar
Publicado: (2006)